Industry

International Day of Older Persons: AOP Health Shines a Light on the Silent Burden of Venous Leg Ulcers

VIENNA–(BUSINESS WIRE)–#AOPHealth—On the United Nations’ International Day of Older Persons, AOP Health draws attention to the often-invisible impact that Chronic Venous Ulcer (CVU) wounds have on older people. CVU are painful, slow-healing wounds that occur on the lower limb and can deprive people of mobility, independence, and dignity. Given the serious consequences, it’s vital to … [Read more…]

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

SCHLIEREN, Switzerland–(BUSINESS WIRE)–Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,” said Anna Sumeray, CEO … [Read more…]

VITAL-HF Trial Demonstrates Remote Digital Intervention Safely Improves Guideline-Directed Therapy in Heart Failure Patients

Story Health by Innovaccer, a digital care platform evaluated in the VITAL-HF trial, demonstrates safe and significant improvements in heart failure therapy optimization. SAN FRANCISCO–(BUSINESS WIRE)–Innovaccer Inc., a leading healthcare AI company, today announced results from the VITAL-HF (Virtual Care to Improve Heart Failure Outcomes) randomized controlled trial, presented today at the Heart Failure Society … [Read more…]

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VYCT #ASTRO25—Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from … [Read more…]

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – − Additional Analyses Reinforce Vutrisiran’s Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran Across a Range of Patients’ Baseline Health Status and … [Read more…]

Brown Books Publishing Group Releases Empowering Longevity Book, Offering a New Path to Aging Gracefully and Healthily

DALLAS–(BUSINESS WIRE)–#book–Board-certified physician Julianna Lindsey, MD FACP, publishes her groundbreaking debut self-help book Radiant Longevity: A Physician’s Protocol for Living Your Best Life (Brown Books Publishing Group; available now). With over 20 years of clinical experience, Dr. Lindsey unveils a holistic, evidence-based approach to aging well, with actionable steps that empower readers to feel their … [Read more…]

MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens

LOS ANGELES–(BUSINESS WIRE)–#ASTRO2025–MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 27 to October 1, 2025, in San Francisco, Calif. The study, conducted by UCLA and other leading academic … [Read more…]

Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple Cancers

SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO). The presentations collectively showcase Artera’s vision to advance the frontier of personalized cancer care, including the first validation of the ArteraAI Prostate Test in an … [Read more…]

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. … [Read more…]

Susan G. Komen® To Host MORE THAN PINK Walk at SeaWorld San Antonio this October

Community Event to Support People with Breast Cancer, Raise Funds for Research and Advocacy Takes Place Saturday, October 18th   SAN ANTONIO–(BUSINESS WIRE)–Susan G. Komen®, the world’s leading breast cancer organization, will convene breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the 2025 San Antonio MORE THAN PINK Walk. This … [Read more…]